Toni Rinow
Director/Board Member at SPROUT AI INC.
Net worth: 32 925 $ as of 2024-03-30
Profile
Toni Rinow currently works at Converge Technology Solutions Corp., as Independent Director from 2022 and Sprout AI, Inc., as Independent Director from 2022.
Dr. Rinow also formerly worked at BetterLife Pharma, Inc., as Chief Executive Officer from 2019 to 2020, Smithkline Beecham Plc, as Medical Representative, ConjuChem, Inc., as Senior Analyst-Business Development from 1999 to 2000, Neptune Wellness Solutions, Inc., as Head-Investor Relations & Corporate Development, Neptune Wellness Solutions, Inc., as Chief Global Operating Officer, CFO & Secretary from 2020 to 2021, Mirati Therapeutics, Inc., as Vice President-Corporate Development from 2001 to 2004, Fonds de Solidarité FTQ, as Senior Vice President from 2004 to 2008, Jubilant DraxImage, Inc., as General Manager from 2018 to 2019, Isologic Innovative Radiopharmaceuticals Ltd., as Chief Operating Officer, and SANUWAVE Health, Inc., as Chief Financial Officer from 2022 to 2024.
Dr. Rinow received her graduate degree and Masters Business Admin degree from McGill University, doctorate degree in 1996 from the University of Montréal, and undergraduate degree from the University of Strasbourg.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-21 | 7,604 ( 0.00% ) | 32 925 $ | 2024-03-30 |
Toni Rinow active positions
| Companies | Position | Start |
|---|---|---|
| SPROUT AI INC. | Director/Board Member | 2022-04-10 |
| CONVERGE TECHNOLOGY SOLUTIONS CORP. | Director/Board Member | 2022-06-22 |
Former positions of Toni Rinow
| Companies | Position | End |
|---|---|---|
| SANUWAVE HEALTH, INC. | Director of Finance/CFO | 2024-03-27 |
| BETTERLIFE PHARMA INC. | Chief Executive Officer | 2020-01-21 |
Jubilant Draximage, Inc.
 Jubilant Draximage, Inc. Pharmaceuticals: MajorHealth Technology Jubilant DraxImage, Inc. engages in the provision of development, manufacturing, and commercialization of radiopharmaceuticals. Its product Drax Exametazime used for the diagnosis and treatment of disease such as intra-abdominal infection and inflammatory bowel disease. The company is headquartered in Kirkland, Canada. | Corporate Officer/Principal | 2018-12-31 |
Fonds de Solidarité FTQ
 Fonds de Solidarité FTQ Investment ManagersFinance Fonds de Solidarité FTQ (Fonds Régional de Solidarité FTQ) is a private equity firm founded in June 1983. The firm is headquartered in Montréal, Quebec. | Private Equity Investor | 2008-03-30 |
| MIRATI THERAPEUTICS | Corporate Officer/Principal | 2004-10-29 |
Training of Toni Rinow
| McGill University | Graduate Degree |
| University of Montréal | Doctorate Degree |
| University of Strasbourg | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| NEPTUNE WELLNESS SOLUTIONS INC. | Health Technology |
| BETTERLIFE PHARMA INC. | Health Technology |
| SANUWAVE HEALTH, INC. | Health Technology |
| CONVERGE TECHNOLOGY SOLUTIONS CORP. | Technology Services |
| SPROUT AI INC. | Producer Manufacturing |
| Private companies | 6 |
|---|---|
Smithkline Beecham Plc
 Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK. | Health Technology |
ConjuChem, Inc.
 ConjuChem, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem, Inc. is a biotechnology company that has developed the Drug Affinity Complex (DAC™) Technology, a platform enabling the rapid creation of improved, patentable drugs from existing small organic compounds or peptides. | Health Technology |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Fonds de Solidarité FTQ
Fonds de Solidarité FTQ Investment ManagersFinance Fonds de Solidarité FTQ (Fonds Régional de Solidarité FTQ) is a private equity firm founded in June 1983. The firm is headquartered in Montréal, Quebec. | Finance |
Jubilant Draximage, Inc.
Jubilant Draximage, Inc. Pharmaceuticals: MajorHealth Technology Jubilant DraxImage, Inc. engages in the provision of development, manufacturing, and commercialization of radiopharmaceuticals. Its product Drax Exametazime used for the diagnosis and treatment of disease such as intra-abdominal infection and inflammatory bowel disease. The company is headquartered in Kirkland, Canada. | Health Technology |
Isologic Innovative Radiopharmaceuticals Ltd.
 Isologic Innovative Radiopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Isologic Innovative Radiopharmaceuticals Ltd. operates as a radiopharmaceutical company. The company is headquartered in Burlington, Canada. | Health Technology |
- Stock Market
- Insiders
- Toni Rinow
